CLSD - Clearside Biomedical - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

97.41M

Cash

35.36M

Avg Qtr Burn

-4.693M

Short % of Float

0.18%

Insider Ownership

7.43%

Institutional Own.

28.97%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
XIPERE (CLS-TA) Details Macular edema	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
belzupacap saratalocan (bel-sar) (AU-011) Details Primary Choroidal Melanoma, Cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CLS-AX Details Wet age-related macular degeneration , Age-related macular degeneration	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-RGX-314 Details Diabetic retinopathy	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RGX-314 Details Wet age-related macular degeneration , Age-related macular degeneration	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.